otilimab development codes fully human antibody developed biotechnology company also referred hucal antibody hucal standing human combinatorial antibody library technology used generate monoclonal antibodies otilimab directed granulocytemacrophage colony stimulating factor gmcsf monomeric glycoprotein functioning cytokine promoting proliferation activation macrophages neutrophils otilimab monoclonal antibody specifically binds gmcsf consequently neutralised incapable binding targeted inflammatory cells order allow proliferation activation following induction inflammation cytokines eg tnfα chemotaxis via chemokines eg tissue degradation caused eg mmps b cell response following upregulated mhc ii level beyond role natural immune pathways gmcsf shown involved autoimmune diseases multiple sclerosis ms rheumatoid arthritis ra cases gmcsf levels elevated mediate increased production proinflammatory elements cytokines chemokines proteases factor also known involved osteoarthritis hand research thus working molecular target treatment disorders notably immunotherapy monoclonal antibody therapy known efficient autoimmune diseases already exist treatments rheumatoid arthritis monoclonal antibodies ie infliximab adalimumab drugs targeting gmcsf tnfα another cytokine involved disease however major involvement tnfα immunity makes suppression delicate diminishes immune defenses treated patients potential new infections may allow reactivation latent ones hepatitis b tuberculosis number reported cases severe side effects including fatal ones led fda instruct tight monitoring patients treatment tnfinhibiting drugs nevertheless another way circumvent outcomes may target alternate cytokine multiple sclerosis ms gmcsf produced helper cells able cross bloodbrain barrier bbb bind macrophages surface along proinflammatory events participate central nervous system cns inflammation process typically occurring ms numerous existing monoclonal antibodies used treatment multiple sclerosis natalizumab targets daclizumab alemtuzumab binding αsubunit receptor surface mature lymphocytes ocrelizumab marker however frequent adverse effects notified including secondary autoimmune suggest uncovering new molecular target monoclonal antibody therapy would welcomed research improved treatment ms otilimab currently undergoing clinical trials determine whether could used treatment far shown generally well tolerated relapsingremitting multiple sclerosis rrms secondary progressive multiple sclerosis spms patients indeed teaes treatmentemergent adverse events observed mild moderate isnt evidence immunogenecity either antiotilimab antibodies detected patients following treatment results provide class evidence regards acceptable tolerance ms patients reveal otilimab remains fitted candidate treatment multiple httpsenwikipediaorgwikiotilimab